Yuhan Corporation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yuhan Corporation sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Yuhan Corporation: 3 sponsored US clinical trials, 2 recruiting.
Yuhan Corporation sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is NSCLC (Non-small Cell Lung Cancer), with 1 trials.
Upper-quartile sponsor footprint
Yuhan Corporation sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
NCT06616766
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
NCT05523947
AME Study of [14C]-YH4808 in Healthy Male Subjects
NCT01825707
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Therapeutic Areas
What is open in the Yuhan Corporation pipeline
2 recruiting of 3 indexed (67% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: NSCLC (Non-small Cell Lung Cancer) (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yuhan Corporation: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Yuhan Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this Yuhan Corporation page
3 registered trials is a research-attention snapshot, not an endorsement of Yuhan Corporation or any single study.
- 2 of Yuhan Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- NSCLC (Non-small Cell Lung Cancer) is the condition Yuhan Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See NSCLC (Non-small Cell Lung Cancer) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yuhan Corporation pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.